Skip to main content
OpenTrials
Completed

NCT Number: NCT01177826

Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children

The purpose of this study is to assess vaccine effectiveness of Rotarix in preventing rotavirus severe gastroenteritis among hospitalized infants, in Belgium.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 week–5 year

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site, Antwerp, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For confirmed cases:

  • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of hospital admission.
  • Child admitted at the study hospital for SGE during the study period.
  • Onset of SGE ≤ 14 days prior to admission.
  • Written informed consent obtained and signed from the parent or guardian of the child.
  • Stool samples collected during the first 48 hours of hospitalisation and then tested positive for RV by PCR.

For controls:

  • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of the hospital admission or visit to the hospital outpatient clinic.
  • Hospitalised or visiting the hospital outpatient clinic for non-GE causes at the same hospital during the same time-period, as the probable case.
  • Born within ±2 weeks from the date of birth of the case. If the list of children born within ±2 weeks is exhausted, then the range will be extended to ±4 weeks. In case a suitable control is not found even then, the range will be extended to ±6 weeks.
  • Written informed consent obtained and signed from the parent or guardian of the child.

Exclusion criteria

For cases:

  • Child has previously participated as a case or a control in this study, either in the same hospital or in another study hospital.
  • Onset of SGE >48 hours after admission to the hospital (nosocomial infections).
  • Child with a condition where rotavirus vaccination would be contraindicated.

For controls:

  • Child has participated in the past as a case or control in this study, either in the same hospital or in another study hospital.
  • Child who has symptoms of GE/ SGE during current hospital stay/ visit to the hospital outpatient clinic or on the day of interview of his/her parent or guardian.
  • Child with a condition where rotavirus vaccination would be contraindicated.

Treatment and study plan

Sample Collection

Procedure

Stool sample

Primary outcomes

  1. Occurrence of PCR-confirmed rotavirus (RV) severe gastroenteritis (SGE) in children fully vaccinated with Rotarix or in unvaccinated children

    Time frame: More than 14 days after receipt of vaccine

Secondary outcomes

  1. Occurrence of PCR-confirmed RV SGE in children who received one or two doses of Rotarix or in unvaccinated children

    Time frame: More than 14 days after receipt of vaccine

  2. Occurrence of PCR-confirmed RV SGE in children who received at least one dose of Rotarix or Rotateq in unvaccinated children

    Time frame: More than 14 days after receipt of vaccine

  3. Occurrence of SGE due to RV among children born after 01 October 2006, at least 14 weeks of age and admitted to hospital

    Time frame: Average time frame: 1 year from the date of subject enrolment

  4. Occurrence of co-infections with other organisms among children born after 1 October 2006, at least 14 weeks of age and hospitalized with PCR-confirmed RV SGE

    Time frame: Average time frame: 1 year from the date of subject enrolment

  5. Occurrence of PCR-confirmed RV SGE by age and month of year, among children born after 01 October 2006, at least 14 weeks of age and admitted to the hospital

    Time frame: Average time frame: 1 year from the date of subject enrolment

  6. Occurrence of RV serotypes among hospitalized PCR-confirmed RV SGE children born after 01 October 2006 and at least 14 weeks of age

    Time frame: Average time frame: 1 year from the date of subject enrolment

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Aug 9, 2010
Registry last updated
Jan 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.